- Policy
- Samsung Bioepis’s Soliris biosimilar is introduced
- by Lee, Tak-Sun Mar 25, 2024 05:59am
- The cost of Soliris (eculizumab), a drug known for its high price, is expected to drop significantly with the introduction of its biosimilar. The original Soliris will also cut its price by 30% in line with the expansion of its reimbursement benefit to cover neuromyelitis optica, to compete with its biosimilars. According to industry s
- Policy
- Economic benefits paid to doctors to be publicly disclosed
- by Lee, Jeong-Hwan Mar 22, 2024 06:08am
- On the 21st, the government announced the guidelines for the public disclosure of expenditure reports on the legitimate financial benefits paid by pharmaceutical and medical device companies to doctors and pharmacists that will be disclosed in December. The guidelines stipulate the detailed schedule, content, and method for disclosure of
- Policy
- Enhertu’s price falls to KRW 70 mil range with reimb
- by Lee, Tak-Sun Mar 22, 2024 06:06am
- The list price of the petitioned anti-cancer drug Enhertu was reportedly set at KRW 1.4 million per vial. This is significantly cheaper than the non-reimbursed price of KRW 2.3 million. In addition, the National Health Insurance Service (NHIS) will apply a risk-sharing agreement (RSA) system for the reimbursement of the drug, so the actua
- Policy
- National Essential Medicines to be categorized into 4 groups
- by Lee, Hye-Kyung Mar 21, 2024 05:53am
- The Ministry of Food and Drug Safety (MFDS) plans to categorize national essential drugs into 4 groups and conduct regular level assessments to better manage the drugs. According to the 'Research Service to Prepare a Measure to Classify and Manage the National Essential Medicine ‘ that was recently announced by MFDS, the authorities will dis
- Policy
- Gov’t raises price of Harmonilan due to unstable supply
- by Lee, Tak-Sun Mar 21, 2024 05:52am
- The insurance ceiling price of the enteral nutrition formula Harmonilan (B Braun Korea), which the company has been experiencing difficulties in ensuring supply and demand recently, is expected to rise from April. The company had continuously been applying to register the drug as a ‘drug shortage prevention drug' and preserve productio
- Policy
- MSD withdraws SGLT2 inhibitors in a row
- by Lee, Hye-Kyung Mar 20, 2024 05:44am
- MSD Korea is facing tough competition in the market for SGLT-2 inhibitors in South Korea. MSD decided that they will discontinue the supply of Steglatro Tab 5 mg and 'Stegluzan Tab 5/100 mg (ertugliflozin plus sitagliptin)' after voluntarily withdrawing 'Steglatro Tab 15 mg (ertugliflozin)' and metformin combination therapy, 'Segluromet,' la
- Policy
- President Yoon stands on expanding quota to 2,000
- by Lee, Jeong-Hwan Mar 20, 2024 05:44am
- President Yoon Suk Yeol reaffirmed the government’s plan to increase the medical school enrollment quota to 2,000 and stated, “Korea’s policy related to the number of doctors is not meeting the standards of the current era and actual needs, repeating the history of failure. Doctors’ licenses should not be used as a tool to intimidate K
- Policy
- Essential medical devices will be designated by next year
- by Lee, Hye-Kyung Mar 20, 2024 05:44am
- The Ministry of Food and Drug Safety is considering establishing a system to designate national essential medical devices. More specifically, the government plans to set a specific scope of medical devices that are essential for healthcare, such as rapid antigen test kits and life support devices that were necessary during COVID-19 but were diff
- Policy
- Liver cancer therapy, ‘Stivarga’ set for 2nd RSA renewal
- by Lee, Tak-Sun Mar 19, 2024 05:44am
- It has been reported that a risk sharing agreement (RSA) has been renewed for the second time for Stivarga (regorafenib; Bayer Korea), a second-line treatment for liver cancer. The news comes two months before the reimbursable RSA contract for Stivarga is set to expire on May 31st. According to industry sources on the 18th, the Nationa
- Policy
- Sotyktu, Adtralza set for reimbursement listing
- by Lee, Tak-Sun Mar 18, 2024 05:49am
- Two drugs, plaque psoriasis drug 'Sotyktu (deucravacitinib)' and atopic dermatitis drug 'Adtralza (tralokinumab)' have completed the negotiation with the National Health Insurance Service (NHIS) and may soon be listed for reimbursement. Additionally, the upper price limit of Soliris (eculizumab) is expected to be reduced following the e
